Header Logo

Connection

NORIHIRO WATANABE to Humans

Back to Details
This is a "connection" page, showing publications NORIHIRO WATANABE has written about Humans.
NORIHIRO WATANABE
Connection Strength
0.184
Humans
  1. Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
    View in: PubMed
    Score: 0.024
  2. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
    View in: PubMed
    Score: 0.022
  3. Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol. 2022; 13:876339.
    View in: PubMed
    Score: 0.021
  4. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There? Cancer J. 2021 Mar-Apr 01; 27(2):176-181.
    View in: PubMed
    Score: 0.020
  5. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Mol Ther. 2021 02 03; 29(2):505-520.
    View in: PubMed
    Score: 0.019
  6. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019 11 28; 7(1):330.
    View in: PubMed
    Score: 0.018
  7. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 04 25; 143(17):1726-1737.
    View in: PubMed
    Score: 0.006
  8. Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
    View in: PubMed
    Score: 0.006
  9. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma. J Immunother Cancer. 2023 01; 11(1).
    View in: PubMed
    Score: 0.006
  10. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).
    View in: PubMed
    Score: 0.005
  11. Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
    View in: PubMed
    Score: 0.005
  12. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
    View in: PubMed
    Score: 0.005
  13. Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397.
    View in: PubMed
    Score: 0.005
  14. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018 08; 8(8):972-987.
    View in: PubMed
    Score: 0.004
  15. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34.
    View in: PubMed
    Score: 0.004
  16. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
    View in: PubMed
    Score: 0.004
  17. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
    View in: PubMed
    Score: 0.004
  18. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
    View in: PubMed
    Score: 0.004
  19. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.